AlanPLyssMD

Board-certified in internal medicine and medical oncology. Principal Investigator of Heartland Cancer Research, a National Cancer Institute-designated Community Clinical Oncology Program (CCOP) at Missouri Baptist Medical Center. Associate Professor of C

Join to view full profile

Dr. Lyss is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lyss' full profile

Already have an account?

Office
3015 N Ballas Rd
Missouri Baptist Cancer Center
Saint Louis, MO 63131
Phone+1 314-996-5425

Fax+1 314-996-4689

Education & Training

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 1979 - 1982
Ohio State University HospitalResidency, Internal Medicine, 1976 - 1979
Washington University in St. Louis School of MedicineClass of 1976

Certifications & Licensure

MO State Medical License 1982 - 2025
PA State Medical License 1980 - 1984
OH State Medical License 1977 - 1979
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2013
Top MD Consumers Checkbook

Clinical Trials

Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer Start of enrollment: 1999 Mar 01
Completed
Phase 2
Cytogenetic Studies in Acute Leukemia and Multiple Myeloma Start of enrollment: 1984 Jun 01
Active, not recruiting
S0220: Chemoradiotherapy Followed By Surgery and Docetaxel in Treating Patients With Pancoast Tumors Start of enrollment: 2003 Jul 01
Completed
Phase 2
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
Completed
Phase 3
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01
Active, not recruiting
Phase 3
Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer Start of enrollment: 2006 Sep 15
Completed
Phase 2
S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo Start of enrollment: 2006 Oct 01
Completed
Phase 3
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer Start of enrollment: 2007 May 01
Completed
Phase 2
L-Arginine Supplements in Treating Women Who Are Cancer Survivors Start of enrollment: 2007 May 01
Completed
Not Applicable
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor Start of enrollment: 2007 Dec 01
Active, not recruiting
Phase 3
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
Active, not recruiting
Phase 3
Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer Start of enrollment: 2008 May 15
Active, not recruiting
Phase 3
Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia Start of enrollment: 2008 Jan 15
Completed
Phase 2
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2008 Feb 29
Active, not recruiting
Phase 3
Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer Start of enrollment: 2008 Jun 01
Completed
Phase 3
Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy Start of enrollment: 2008 Jun 15
Completed
Phase 3
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Start of enrollment: 2008 Apr 15
Completed
Phase 2
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer Start of enrollment: 2008 Oct 13
Completed
Phase 3
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Start of enrollment: 2009 Jan 29
Active, not recruiting
Phase 3
Acute Pain Caused by Paclitaxel in Patients With Cancer Start of enrollment: 2009 Feb 01
Completed
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery Start of enrollment: 2009 May 15
Active, not recruiting
Phase 2
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2009 Apr 01
Completed
Phase 1, Phase 2
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases Start of enrollment: 2008 Dec 01
Completed
Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes Start of enrollment: 1996 May 01
Active, not recruiting
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2009 Jul 15
Terminated
Phase 3
RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer Start of enrollment: 2010 Mar 31
Active, not recruiting
Phase 3
Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma Start of enrollment: 2010 Apr 01
Completed
Phase 2
Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2009 Oct 01
Completed
Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab Start of enrollment: 2010 Mar 01
Completed
Phase 2
Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery Start of enrollment: 2010 Mar 01
Terminated
Phase 3
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Start of enrollment: 2010 Apr 05
Active, not recruiting
Phase 3
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia Start of enrollment: 2011 Apr 27
Terminated
Phase 2
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2010 Feb 15
Completed
Phase 3
Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2010 Feb 01
Terminated
Phase 3
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy Start of enrollment: 2010 Jun 01
Completed
Phase 3
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Completed
Phase 3
Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery Start of enrollment: 2010 Apr 12
Active, not recruiting
Phase 3
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Start of enrollment: 2010 Oct 25
Completed
Phase 3
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01
Active, not recruiting
Phase 3
Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer Start of enrollment: 2011 Jan 07
Completed
Phase 2
Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma Start of enrollment: 2010 May 01
Completed
Phase 2
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Start of enrollment: 2011 Feb 14
Completed
Phase 3
Sulfasalazine in Preventing Acute Diarrhea in Patients With Cancer Who Are Undergoing Pelvic Radiation Therapy Start of enrollment: 2011 Apr 01
Completed
Phase 3
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy Start of enrollment: 2010 Sep 15
Terminated
Phase 3
Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery Start of enrollment: 2010 Oct 15
Completed
Phase 2
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Start of enrollment: 2011 May 25
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer Start of enrollment: 2011 Jan 01
Terminated
Phase 3
Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma Start of enrollment: 2011 Apr 08
Active, not recruiting
Phase 2
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer Start of enrollment: 2012 Feb 01
Completed
Phase 2
PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery Start of enrollment: 2012 Jun 12
Active, not recruiting
Phase 2, Phase 3
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Start of enrollment: 2012 Jun 04
Terminated
Phase 3
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer Start of enrollment: 2012 May 01
Active, not recruiting
Phase 3
Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer Start of enrollment: 2012 Jul 01
Completed
Phase 2
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Start of enrollment: 2012 Aug 08
Active, not recruiting
Phase 3
Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme Start of enrollment: 2012 Nov 01
Completed
Phase 1, Phase 2
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Start of enrollment: 2013 Jul 08
Completed
Phase 2
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma Start of enrollment: 2013 Oct 01
Completed
Phase 2
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic Start of enrollment: 2014 Mar 29
Active, not recruiting
Phase 3
Dabrafenib and Trametinib for the Treatment of Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2014 Sep 19
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

23 citations
Brain damage and associated behavioral deficits following the administration of L-cysteine to infant rats
Lawrence G. Shapre, John W. Olney, Cathy Ohlendorf, Alan P. Lyss, Marianne Zimmerman
Pharmacology, Biochemistry, and Behavior. 1975-03-01
179 citations
Positron Tomographic Assessment of 16α-[18F] Fluoro-17β-Estradiol Uptake in Metastatic Breast Carcinoma
A H McGuire, Farrokh Dehdashti, Barry A. Siegel, Alan P. Lyss, James W. Brodack
Journal of Nuclear Medicine. 1991-08-01
303 citations
Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer
Panos Fidias, Shaker R. Dakhil, Alan P. Lyss, David M. Loesch, David M. Waterhouse
Journal of Clinical Oncology. 2009-02-01

Authored Content

I-sPY2 Reveals High pCR Rates in Difficult-to-Treat Breast CancersAugust 2024
Adjuvant Camrelizumab Improves Outcomes in Nasopharyngeal CarcinomaAugust 2024
ChatGPT Produces Mixed Results for Gynecologic CancersApril 2024
ctDNA Testing in Colorectal Cancer Deemed Promising but Not Ready for Prime TimeMarch 2023
Duration of ET Tied to Benefit in DCIS, but Young Patients May Reject ETNovember 2022
Crisis in Oncology Research Demands Urgent Action, Stakeholders SayNovember 2022
Blood Test Shows Promise for Detecting Cancers Without Approved Screening TestsOctober 2022
How to Improve Outcomes for Older Patients with Ovarian CancerAugust 2022
High-Deductible Health Plans Linked to Delayed Diagnosis of Metastatic CancerJune 2022
Can Aspirin Prevent Gastric Cancer?February 2022
Phase 3 Studies Herald More Options for Metastatic Breast CancerJanuary 2022
Do Antibiotics Affect Outcomes of Immunotherapy in Lung Cancer?December 2021
Genetic Differences May Partly Explain Racial/Ethnic Disparities in Early-Onset Colorectal CancerNovember 2021
First-Line Immunotherapy Continues to Best Chemo in Malignant Pleural MesotheliomaOctober 2021
Efforts to Close the ‘AYA Gap’ in LymphomaOctober 2020
The Scope of Under- and Overtreatment in Older Adults with CancerOctober 2020
Join now to see all

Press Mentions

Using Telehealth to Deliver Palliative Care to Cancer PatientsNovember 17th, 2020
The Law of Unintended ConsequencesOctober 11th, 2019
Studies Reinforce Clinical Experience and IntuitionAugust 30th, 2019
Join now to see all